Comparative study of sarcomatoid carcinoma and carcinosarcoma of the pancreas: a population-based study

Xinchun Liu¹, Haoran Wang², Rongchao Ying¹,²

¹Department of General Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China; ²Department of General Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China

Contributions: (I) Conception and design: R Ying; (II) Administrative support: R Ying; (III) Provision of study materials or patients: R Ying; (IV) Collection and assembly of data: X Liu, H Wang; (V) Data analysis and interpretation: X Liu, H Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Rongchao Ying. Department of General Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical University, Huansha Road 261, Hangzhou 310006, China. Email: ying.rongchao@foxmail.com.

Background: Sarcomatoid carcinoma (SCP) and carcinosarcoma (CSP) of the pancreas are extremely rare entities and little is known about their characteristics. Using a population-based cancer registry, we aimed at improving our understanding of these entities with a focus on the comparison between these two entities.

Methods: Patients with SCP or CSP were identified through the Surveillance Epidemiology and End Results (SEER) database. Demographic and clinical characteristics were collected and compared. Survival was compared using the Kaplan-Meier method and analyzed using the log-rank test and Cox proportional hazards models.

Results: A total of 85 patients with SCP and 32 patients with CSP were included in the study. There was no difference in the patient age, race distribution, year of diagnosis, primary site, tumor size, tumor stage, receipt of chemotherapy and receipt of radiotherapy between the two groups. However, more patients with CSP received surgical treatment (P<0.001) when compared to patients with SCP. Overall survival was comparable between the two groups (P=0.562) with a 1-year survival rate of 20.8% and 22.2% for SCP and CSP, respectively. Multivariate analysis showed that surgical resection was independent prognostic factor of both SCP (HR: 0.34, P=0.017) and CSP (HR: 0.17, P=0.017). Chemotherapy was a prognostic factor of CSP in univariate analysis, but not of SCP.

Conclusions: SCP and CSP are rare malignant tumors of the pancreas with a dismal prognosis. Surgical resection was the common prognostic factor and was recommended when possible.

Keywords: Sarcomatoid carcinoma; carcinosarcoma; pancreas; Surveillance, Epidemiology, and End Results (SEER)

Submitted Feb 19, 2022. Accepted for publication May 17, 2022.
doi: 10.21037/tcr-22-410
View this article at: https://dx.doi.org/10.21037/tcr-22-410

Introduction

With approximately 62,210 new cases and 49,830 deaths in 2022, pancreatic cancer was projected to be the third leading cause of cancer-related death in the United States (1). Both sarcomatoid carcinoma (SCP) and carcinosarcoma (CSP) of the pancreas are rare histological subtypes of pancreatic cancer. Histologically, SCP is an epithelial carcinoma with a sarcoma-like appearance (2), characterized by a predominant composition of spindle cells having morphologic features with epithelial derivation, such as epithelial markers and epithelial ultrastructural features (3-5). In contrast, CSP consists of two pathologically-distinct epithelial and mesenchymal components, which were distinguished by the mutually exclusive expression of cytokeratin and vimentin (6,7). Together, SCP and CSP were classified under the
category of undifferentiated carcinoma of the pancreas by the World Health Organization (WHO) classification (8).

However, little of pathogenesis and response to different types of therapy was known about both of these two entities. Due to the rarity, previous studies in the literature were limited to case reports and small case series and sometimes were inappropriately used interchangeably [2–5]. Li et al. recently reported the so far largest case series of CSP from a single center with a total of nine cases (9), while the so far largest single-center case series of SCP by Blair et al. had a total of eight cases (3). While some authors suggest that out of practical purposes, CSP and SCP can be used interchangeably (5,10), the other authors argue that these two entities are different subtypes of pancreatic cancer and should not be confused with each other (11). Recently, using the Surveillance, Epidemiology, and End Results (SEER) database, Alhatem et al. reported 39 cases of CSP, which is the largest case series so far (12). However, there are no reports on SCP using the SEER database. No direct comparison between these two entities was performed before.

In the present study, to better understand SCP, using data from the SEER database, we evaluated the demographics, treatment methods, and survival outcomes of SCP and CSP and performed a direct comparison of these two diseases. We present the following article in accordance with the STROBE reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-410/rc).

**Methods**

**Data source**

This is a retrospective study using the population-based National Cancer Institute’s SEER database. The SEER database collects cancer incidence and survival data from population-based cancer registries that cover approximately 34.6% of the U.S. population. In the present study, the ASCII text version of the data: SEER 18, 1975–2016 was downloaded and used for data mining.

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Because data from SEER were de-identified and publicly available for research purposes, ethical approval from the Institutional Review Board was exempted, and no informed consent was signed for this study.

**Cohort selection**

As treatment strategy, as well as the inspection and diagnosis method, have changed a lot after 2000, only cases diagnosed after 2000 were included in the present study. The codes of the International Classification of Oncology, third edition (ICD-O-3/WHO 2008) were used to identify eligible cases. Topographic codes C25.0-C25.4 and C25.7-C25.9 were used to identify primary pancreatic cancer cases. Topographic codes 8033 and 8980 were used to identify sarcomatoid carcinoma (a synonym of pseudosarcomatous carcinoma) and carcinosarcoma of the pancreas, respectively. Patients with a histologically confirmed diagnosis were included in the study, while patients with a diagnosis reported by autopsy only/death certificate only were excluded from the analysis.

Demographic data including age at diagnosis, year of diagnosis, sex, race, tumor location within the pancreas and tumor stage were collected. Since TNM staging information was only available for patients who were diagnosed in 2004 and afterward, SEER historic stage was adopted for tumor stage, which was reported from 1975 to 2015. According to the SEER historical staging classification, tumor stage was divided into three groups: localized, regional, and distant stage (13,14).

Treatment data included receipt of cancer-directed surgery (CDS), use of adjuvant chemotherapy and use of adjuvant radiation was collected. Survival data included vital status, cause of death, and survival time in months were collected. CDS was defined by any surgery performed on the primary tumor as a part of curative or radical treatment (15).

**Statistical analysis**

All data analyses were performed using Stata/MP 13.1 for Windows (StataCorp LP, College Station, TX, USA). Continuous variables were displayed as mean ± standard deviation or median (interquartile range) and were compared using student t-test or rank-sum test. Categorical variables were displayed as frequency and proportion and were compared using chi-square test. Overall survival rate and median overall survival were calculated using the Kaplan–Meier method and compared using log-rank test. Cox proportional hazard regression was used multivariate analysis to determine independent predictors of overall
survival. Variables with a $P<0.10$ in univariate analysis were selected for multivariate analysis. A two-sided $P<0.05$ was considered to be statistically significant.

**Results**

**Clinicopathological characteristics of patients**

Between 2000 and 2016, a total of 85 patients who were histologically diagnosed with SCP were identified from the SEER database, and 32 patients with SCP were identified during the same period (Figure 1). The demographic and clinicopathological characteristics of the two entities are shown in Table 1.

Between the two subtypes of cancer (SCP versus CSP), patients have similarly distributions in age at diagnosis (69.5±11.9 versus 68.1±11.1 years, $P=0.552$), sex (50.6% female versus 50.0% female, $P=0.955$), race (82.4% White people versus 84.4% White people, $P=0.833$), tumor location in the pancreas (45.9% versus 40.6% at head, $P=0.581$) and tumor size (6.4±3.7 versus 6.4±3.7 cm, $P=0.989$). In addition, there was also no significant difference in terms of the year of diagnosis ($P=0.581$) or the tumor stage ($P=0.158$).

Regarding the treatment modality, patients with SCP were significantly less likely to undergo CDS (32.9% versus 78.1%, $P<0.001$), but with a similar chance to receive chemotherapy ($P=0.892$) and radiation therapy ($P=0.877$).

**Survival outcomes**

The observed overall survival was similar in patients with SCP compared with those with CSP in the overall cohort ($P=0.562$) (Figure 2A). The survival analysis revealed that the median overall survival was 3 months (95% CI: 2–5 months) and 8 months (95% CI: 4–9 months) for SCP and CSP, respectively. The overall survival rates in patients with SCP were 20.8% (95% CI: 11.9–31.5%) at 1 year and 15.9% (95% CI: 8.1–25.9%) at 3 years; in patients with CSP were 22.2% (95% CI: 9.1–38.8%) at 1 year and 11.1% (95% CI: 2.8–28.8%) at 3-year. Median overall survival comparisons for different subgroups of all factors between SCP and CSP were shown in Table 2. Survival comparisons for patients who underwent CDS (Figure 2B), patient with (Figure 2C) or without (Figure 2D) chemotherapy did not show significant difference.

**Prognostic factors**

In patients with SCP, univariate analysis showed that tumor stage and surgery were prognostic factors of overall survival. Subsequent multivariate analysis indicated that surgery was the only independent prognostic factor of overall survival (HR: 0.34; 95% CI: 0.14–0.83; $P=0.017$; Table 3). In patients with CSP, univariate analysis showed that not only tumor stage and surgery but also chemotherapy and race were prognostic factors of overall survival. Subsequent
### Table 1 Patient demographics and tumor characteristics

| Variables                   | SCP (n=85), n (%) | CSP (n=32), n (%) | P     |
|-----------------------------|-------------------|-------------------|-------|
| Age, years                  | 69.5±11.9         | 68.1±11.1         | 0.552 |
| Sex                         |                   |                   | 0.955 |
| Female                      | 43 (50.6)         | 16 (50.0)         |       |
| Male                        | 42 (49.4)         | 16 (50.0)         |       |
| Race                        |                   |                   | 0.833 |
| White                       | 70 (82.4)         | 27 (84.4)         |       |
| Black                       | 11 (12.9)         | 3 (9.4)           |       |
| Asian/Pacific Islander      | 4 (4.7)           | 2 (6.2)           |       |
| Year of diagnosis           |                   |                   | 0.368 |
| 2000–2009                   | 27 (31.8)         | 13 (40.6)         |       |
| 2010–2016                   | 58 (68.2)         | 19 (59.4)         |       |
| Primary site                |                   |                   | 0.581 |
| Head                        | 39 (45.9)         | 13 (40.6)         |       |
| Body/tail                   | 26 (30.6)         | 13 (40.6)         |       |
| Other†                      | 20 (23.5)         | 6 (18.8)          |       |
| Tumor size, cm*             | 6.4±3.7           | 6.4±3.7           | 0.989 |
| SEER stage                  |                   |                   | 0.158 |
| Localized                   | 7 (9.0)           | 3 (9.7)           |       |
| Regional                    | 24 (30.8)         | 14 (45.2)         |       |
| Distant                     | 47 (60.3)         | 13 (41.9)         |       |
| Unknown                     | 0 (0.0)           | 1 (3.2)           |       |
| CDS                         |                   |                   | <0.001|
| Yes                         | 28 (32.9)         | 25 (78.1)         |       |
| No                          | 57 (67.1)         | 7 (21.9)          |       |
| Chemotherapy                |                   |                   | 0.892 |
| Yes                         | 36 (42.3)         | 14 (43.7)         |       |
| No/unknown                  | 49 (57.7)         | 18 (56.3)         |       |
| Radiation                   |                   |                   | 0.877 |
| Yes                         | 6 (7.1)           | 2 (6.3)           |       |
| No/unknown                  | 79 (92.9)         | 30 (93.7)         |       |

†, data are shown as mean ± standard deviation; †, including other specified parts of pancreas (Code of the International Classification of Oncology, third edition: C257), Overlapping lesion of pancreas (C258), and Pancreas, NOS (C259); *, exact data available for 74 cases of SCP and 28 cases of CSP; †, data not available for 8 cases who were diagnosed in 2016. SCP, sarcomatoid carcinoma of the pancreas; CSP, carcinosarcoma of the pancreas; SEER, Surveillance Epidemiology and End Results; CDS, cancer-directed surgery.
multivariate analysis indicated that CDS (HR: 0.17; 95% CI: 0.04–0.72; P=0.017) was the only independent prognostic factor of CSP, but race, tumor stage, and chemotherapy were not any more.

**Discussion**

SCP and CSP are extremely rare histological subtypes of pancreatic cancer. Using data from the population-based SEER database, this study is the first to be able to perform direct comparisons of clinicopathological characteristics, treatment modalities and survival outcomes between these two entities. Both SCP and CSP are likely to occur in the late 60s of the patients with a nearly even distribution in sex. There are no significant differences in race, the year of diagnosis, primary tumor location, tumor size, SEER stage, receipt of chemotherapy and receipt of radiation between the two entities. Overall survival was also comparable between the two entities. However, when compared to patients with SCP, patients with CSP were more likely to undergo CDS.

SCP is characterized by a predominance of spindle cells and sarcomatous morphologic features with epithelial derivation. CSP is characterized by epithelial (carcinomatous) and mesenchymal (sarcomatous) components. The pathogenesis of both SCP and CSP remains to be elucidated. SCP is believed to have an entirely epithelial origin (11,16). By using genomic and molecular analysis, recent studies suggested that the two components of CSP have a monoclonal origin since they have the same KRAS and TP53 mutations (6,9). Other proposed pathogenesis theories of CSP include combination theory, which denotes that a combination of epithelial and mesenchymal cells underwent early differentiation from a
Table 2  Median overall survival for different subgroups

| Subgroups                  | SCP, months (95% CI) | CSP, months (95% CI) | P    |
|----------------------------|----------------------|----------------------|------|
| Entire cohort              | 3 (2, 5)             | 8 (4, 9)             | 0.562|
| Age, years                 |                      |                      |      |
| <70                        | 3 (3, 5)             | 8 (2, 16)            | 0.244|
| ≥70                        | 5 (2, 8)             | 5 (3, 8)             | 0.617|
| Sex                        |                      |                      |      |
| Female                     | 3 (2, 6)             | 6 (3, 12)            | 0.840|
| Male                       | 3 (2, 8)             | 8 (4, 11)            | 0.500|
| Race                       |                      |                      |      |
| White                      | 3 (2, 8)             | 8 (4, 11)            | 0.784|
| Black                      | 2 (1, 5)             | 2 (2, –)             | 0.979|
| Asian/Pacific Islander     | 5 (1, –)             | 4 (4, –)             | 0.501|
| Year of diagnosis          |                      |                      |      |
| 2000–2009                  | 3 (2, 10)            | 6 (3, 11)            | 0.858|
| 2010–2016                  | 3 (2, 6)             | 8 (4, 16)            | 0.413|
| Primary site               |                      |                      |      |
| Head                       | 3 (2, 6)             | 8 (3, 28)            | 0.624|
| Body/tail                  | 5 (2, 6)             | 5 (3, 11)            | 0.985|
| Other†                     | 3 (2, 10)            | 6 (1, –)             | 0.761|
| Tumor size*                |                      |                      |      |
| <6 cm                      | 3 (2, 8)             | 6 (4, 8)             | 0.885|
| ≥6 cm                      | 3 (2, 5)             | 8 (2, 13)            | 0.305|
| SEER stage*                |                      |                      |      |
| Localized                  | 16 (2, –)            | 11 (3, –)            | 0.844|
| Regional                   | 9 (2, 60)            | 9 (6, 16)            | 0.501|
| Distant                    | 2 (2, 3)             | 3 (1, 5)             | 0.936|
| CDS                        |                      |                      |      |
| Yes                        | 10 (6, –)            | 8 (6, 12)            | 0.115|
| No                         | 2 (2, 3)             | 2 (1, –)             | 0.254|
| Chemotherapy               |                      |                      |      |
| Yes                        | 5 (3, 8)             | 9 (6, 13)            | 0.102|
| No/unknown                 | 2 (1, 6)             | 4 (2, 6)             | 0.586|
| Radiation                  |                      |                      |      |
| Yes                        | 5 (2, –)             | 6 (6, –)             | 0.622|
| No/unknown                 | 3 (2, 6)             | 8 (3, 9)             | 0.628|

*, including other specified parts of pancreas (Code of the International Classification of Oncology, third edition: C257), Overlapping lesion of pancreas (C258), and Pancreas, NOS (C259). †, exact data available for 74 cases of SCP and 28 cases of CSP; ‡, data not available for 8 cases who were diagnosed in 2016. SCP, sarcomatoid carcinoma of the pancreas; CSP, carcinosarcoma of the pancreas; CI, confidence interval; SEER, Surveillance Epidemiology and End Results; CDS, cancer-directed surgery.
common stem cell (17,18); collision theory, which denotes that two independently growing carcinomas and sarcomas collide together (19); and transformation theory, which denotes that a section of the carcinoma transforms into a sarcomatous component (20,21). Mesenchymal tumor differentiation exists both in CSP and SCP (5,6). Therefore, the epithelial-mesenchymal transition may play a role in the formation of CSP and SCP (3).

In the present study, we found more patients with CSP received surgical treatment. This might be because that less patients with CSP were diagnosed with distant stage when compared with patients with SCP, although statistically insignificant. We also found that chemotherapy was a prognostic factor of CSP but not of SCP in the univariate analysis. This suggests that these two entities may have different tumor biology and responded differently to chemotherapy. Therefore, we believe SCP and CSP should be regarded as different subtypes of pancreatic cancer and these two terms should not be used interchangeably, although they were classified as the same entity, namely undifferentiated carcinoma of the pancreas by WHO (8). Multivariate analysis showed that CDS was the

| Table 3 | Uni- and multivariate survival analysis                        |
|---------|---------------------------------------------------------------|
| Variables | SCP | Multivariate | CSP | Multivariate |
|          | Univariate* | |    | Univariate* | | Multivariate |
|          | P | HR (95% CI) | P | P | HR (95% CI) | P |
| Age*     | 0.402 | | 0.314 | | |
| Sex†     | 0.983 | | 0.907 | | |
| Race     | 0.306 | | 0.045 | | |
| White    | | | | | |
| Black    | | | | | |
| Asian/Pacific Islander | | | | |
| YOD*     | 0.909 | | 0.256 | | |
| Primary site† | 0.875 | | 0.465 | | |
| Tumor size‡ | 0.556 | | 0.234 | | |
| SEER stage§ | | | | |
| Localized | 0.62 (0.20, 1.94) | | 0.413 | | 0.94 (0.20, 4.46) | | 0.936 |
| Regional | Reference | | Reference | | Reference |
| Distant | 1.33 (0.53, 3.35) | | 0.545 | | 3.13 (0.94, 10.47) | | 0.064 |
| Unknown | | | | | |
| CDS <0.001* | | | | | |
| No/unknown | | | | | |
| Yes | 0.34 (0.14, 0.83) | | 0.017 | | 0.17 (0.04, 0.72) | | 0.017 |
| Chemotherapy | 0.778 | | 0.032 | | |
| Yes | | | | | |
| No/unknown | | | | | |
| Radiation¶ | 0.792 | | 0.719 | | |

*, calculated using the log-rank test; *, <70 versus ≥70 years; †, female versus male; ‡, 2000–2009 versus 2010–2016; §, head of the pancreas versus body/tail versus other sites; †, <6 versus ≥6 cm; ‡, yes versus no/unknown. SCP, sarcomatoid carcinoma of the pancreas; CSP, carcinosarcoma of the pancreas; HR, hazard ratio; CI, confidence interval; YOD, year of diagnosis; SEER, Surveillance Epidemiology and End Results; CDS, cancer-directed surgery.
only independent prognostic factor of both CSP and SCP, which indicating both diseases were surgical disease. This was in line with the findings that patients could achieved long-term survival after margin-negative surgery with or without adjuvant chemotherapy (22-24). However, further results from larger prospective studies are needed.

The findings derived from this study should be interpreted with caution since there were several limitations to this study, which were inherent to the use of the SEER database (25). First, even though this study was the so far largest series comparing SCP and CSP, the sample size was still relatively small due to the rarity of the two entities. Second, a centralized histopathologic review of the diagnosis along with lab examinations and imaging was not possible (26). However, it is reasonable to believe that to make a pathological diagnosis of rare cancer, one or several senior pathologists would be consulted. Therefore, we assumed that the diagnosis was correct in most cases. This assumption probably is the common prerequisite for all SEER-based paper that focus on rare cancers. Third, the data of the variables provided by SEER database is not perfect, especially for radiation therapy and chemotherapy, which is reported that overall sensitivity was 68% for SEER chemotherapy data and 80% for SEER radiation therapy data (27). Fourth, this study had a retrospective design in nature. Therefore, it has a predisposition to potential bias, including the biases associated with unmeasured reasons for receiving or not receiving chemotherapy/radiation therapy. Nevertheless, SEER is still a useful resource that allows for a meaningful study of rare subtypes of pancreatic cancer and this study provided the first comparative investigation that would be difficult to perform otherwise (28,29).

Conclusions

In conclusion, using data from the SEER database, this study was the first to compare the clinicopathological characteristics between SCP and CSP. The analysis found that SCP and CSP are rare malignant tumors of the pancreas with a similar dismal prognosis. SCP and CSP might respond differently to chemotherapy. Surgical resection was the prognostic factor and was recommended when possible. Further prospective large studies were needed.

Acknowledgments

We thank The Surveillance, Epidemiology, and End Results (SEER) Program for providing the information.

Funding: This work was supported by Hangzhou Health Science and Technology Program (A20210271 to Xinchun Liu).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-410/rc

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-410/coif). XL received funding from Hangzhou Health Science and Technology Program (A20210271). The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
2. Yepuri N, Pruekprasert N, Naous R. High-grade malignant pancreatic neoplasm with sarcomatoid features. AME Case Rep 2018;2:39.
3. Blair AB, Burkhart RA, Griffin JF, et al. Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience. J Surg Res 2017;219:238-43.
4. Kane JR, Laskin WB, Matkowskyj KA, et al. Sarcomatoid (spindle cell) carcinoma of the pancreas: A case report and
review of the literature. Oncol Lett 2014;7:245-9.
5. Zhou DK, Gao BQ, Zhang W, et al. Sarcomatoid carcinoma of the pancreas: A case report. World J Clin Cases 2019;7:236-41.
6. Ruess DA, Kayser C, Neubauer J, et al. Carcinosarcoma of the Pancreas: Case Report With Comprehensive Literature Review. Pancreas 2017;46:1225-33.
7. Khan J, Cheng L, House MG, et al. Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas. Curr Oncol 2021;28:5295-303.
8. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182-8.
9. Li J, Wei T, Zhang J, et al. Carcinosarcoma of the pancreas: comprehensive clinicopathological and molecular characterization. HPB (Oxford) 2020;22:1590-5.
10. Rhim AD. Epithelial to mesenchymal transition and the generation of stem-like cells in pancreatic cancer. Pancreatology 2013;13:114-7.
11. Mszyco S, Teng L, Annunziata J, et al. Pancreatic Carcinosarcoma: A Case Report Highlighting Computed Tomography Characteristics. Curr Probl Diagn Radiol 2017;46:342-5.
12. Alhatem A, Quinn PL, Xia W, et al. Pancreatic Carcinosarcoma Clinical Outcome Analysis of the National Cancer Institute Database. J Surg Res 2021;259:62-70.
13. Lv JW, Zhou GQ, Chen YP, et al. Refining the Role of Lymph Node Biopsy in Survival for Patients with Nasopharyngeal Carcinoma: Population-Based Study from the Surveillance Epidemiology and End-Results Registry. Ann Surg Oncol 2017;24:2580-7.
14. Ansari D, Bauden M, Bergström S, et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg 2017;104:600-7.
15. Mahal BA, Inverso G, Aizer AA, et al. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol 2015;26:399-406.
16. Gkountakos A, Simbolo M, Bariani E, et al. Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. Int J Mol Sci 2022;23:1283.
17. Lalonde CS, Wang L, Quigley B, et al. Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature. Chin Clin Oncol 2022;11:8.
18. Tochimoto M, Oguri Y, Hashimura M, et al. S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. Lab Invest 2020;100:682-95.
19. Miyauchi J, Ogura M, Sato M, et al. Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? Pathol Int 2018. [Epub ahead of print].
20. Salibay CJ, Rewerska J, Gupta S, et al. Primary Carcinosarcoma of the Pancreas With CD10-Positive Sarcoma Component. J Investig Med High Impact Case Rep 2017;5:2324709617740906.
21. Bai Q, Zhang X, Zhu X, et al. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour. Histopathology 2016;69:393-405.
22. Toledo PF, Berger Z, Carreño L, et al. Sarcomatoid carcinoma of the pancreas - a rare tumor with an uncommon presentation and course: A case report and review of literature. World J Clin Cases 2021;9:3716-25.
23. Zhu WY, Liu TG, Zhu H. Long-term recurrence-free survival in a patient with pancreatic carcinosarcoma: a case report with a literature review. Med Oncol 2012;29:140-3.
24. Kimura T, Fujimoto D, Togawa T, et al. Sarcomatoid carcinoma of the pancreas with rare long-term survival: a case report. World J Surg Oncol 2020;18:105.
25. Park HS, Lloyd S, Decker RH, et al. Limitations and biases of the Surveillance, Epidemiology, and End Results database. Curr Probl Cancer 2012;36:216-24.
26. Makarova-Rusher OV, Ulahannan S, Greten TF, et al. Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes. Pancreas 2016;45:1432-7.
27. Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER Treatment Data With Medicare Claims. Med Care 2016;54:e55-64.
28. Patel M, Hans HS, Pan K, et al. The Impact of Epidemiological Factors and Treatment Interventions on Survival in Patients With Signet Ring Cell Carcinoma of the Pancreas. Am J Clin Oncol 2018;41:1176-84.
29. Mylonas KS, Nasioudis D, Tsilimigras DI, et al. A population-based analysis of a rare oncologic entity: Malignant pancreatic tumors in children. J Pediatr Surg 2018;53:647-52.

Cite this article as: Liu X, Wang H, Ying R. Comparative study of sarcomatoid carcinoma and carcinosarcoma of the pancreas: a population-based study. Transl Cancer Res 2022;11(7):2061-2069. doi: 10.21037/tcr-22-410